TMDX (TransMedics Group) FCF Margin % : 4.98% (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is TransMedics Group FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. TransMedics Group's Free Cash Flow for the three months ended in Dec. 2024 was $6.1 Mil. TransMedics Group's Revenue for the three months ended in Dec. 2024 was $121.6 Mil. Therefore, TransMedics Group's FCF Margin % for the quarter that ended in Dec. 2024 was 4.98%.

As of today, TransMedics Group's current FCF Yield % is -3.51%.

The historical rank and industry rank for TransMedics Group's FCF Margin % or its related term are showing as below:

TMDX' s FCF Margin % Range Over the Past 10 Years
Min: -412.1 Med: -119.82 Max: -18.33
Current: -18.33

During the past 9 years, the highest FCF Margin % of TransMedics Group was -18.33%. The lowest was -412.10%. And the median was -119.82%.

TMDX's FCF Margin % is ranked worse than
64.37% of 828 companies
in the Medical Devices & Instruments industry
Industry Median: -3.605 vs TMDX: -18.33

TransMedics Group FCF Margin % Historical Data

The historical data trend for TransMedics Group's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransMedics Group FCF Margin % Chart

TransMedics Group Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-119.82

-107.01

-61.76

-79.50

-18.33

TransMedics Group Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-41.29	-49.16	1.71	-38.02	4.98

Competitive Comparison of TransMedics Group's FCF Margin %

For the Medical Devices subindustry, TransMedics Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TransMedics Group's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's FCF Margin % distribution charts can be found below:

* The bar in red indicates where TransMedics Group's FCF Margin % falls into.

Save Embed

;

Save Embed

;

TransMedics Group FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

TransMedics Group's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-80.941	/	441.54
	=	-18.33 %

TransMedics Group's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	6.057	/	121.624
	=	4.98 %

TransMedics Group FCF Margin % Related Terms

Thank you for viewing the detailed overview of TransMedics Group's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

TransMedics Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TransMedics Group Inc (NAS:TMDX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

TMDX:Germany

Address

200 Minuteman Road, Andover, MA, USA, 01810

Website

https://www.transmedics.com

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Executives

Tamer I Khayal	officer: Chief Commercial Officer	TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
Edward M Basile	director	200 MINUTEMAN ROAD, ANDOVER MA 01810
Waleed H Hassanein	director, officer: President & CEO	TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
Nicholas Corcoran	officer: See Remarks	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
James R Tobin	director	C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Anil P. Ranganath	officer: See Remarks	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Stephen Gordon	officer: Chief Financial Officer	200 MINUTEMAN ROAD, ANDOVER MA 01810
David Weill	director	200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Miriam Provost	officer: VP of US Regulatory & FDA Rel.	2000 MINUTEMAN ROAD, ANDOVER MA 01810
John F Carey	officer: VP of Operations	200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Laura Damme	officer: VP, Clinical Affairs	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Stephanie Lovell	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kania Edwin M Jr	director
Rakesh P. Godhani	officer: Chief Digital Officer	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
John F Sullivan	officer: VP of Quality & Engineering	200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810